A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer

Breast Cancer Research

Volumn 12, Issue 5, 2010, Pages

  Yau, Christina ^a   Esserman, Laura ^b   Moore, Dan H ^b   Waldman, Fred ^b   Sninsky, John ^c   Benz, Christopher C ^a,b  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CELERA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

ABO GENE; ACCURACY; ARTICLE; BREAST CANCER; CANCER RELAPSE; CLIC 5 GENE; COHORT ANALYSIS; CONSERVATIVE TREATMENT; CORRELATION ANALYSIS; CXCL 13 GENE; EXOC 7 GENE; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HAPLN 1 GENE; HRBL GENE; HUMAN; HUMAN CELL; MATN 1 GENE; METASTASIS; MULTIGENE FAMILY; PREDICTION; PROGNOSIS; PRRG 3 GENE; PRTN 3 GENE; RFXDC 2 GENE; RGS 4 GENE; RPS 28 GENE; SSX 3 GENE; ZNF 3 GENE; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; GENETICS; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77957759237     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2753     Document Type: Article

References (46)

1. Anders C, Carey LA. Understanding and treating triple-negative breast cancer. Oncology 2008, 22:1233-1243. 2868264, 18980022.
2. Voduc D, Nielsen T. Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options. Clin Breast Cancer 2008, 8:s171-s178. 10.3816/CBC.2008.s.014, 19158038.
3. Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: review. Pathology 2009, 41:40-47. 10.1080/00313020802563510, 19089739.
4. Chen XS, Ma CD, Wu JY, Yang WT, Lu H, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer. Tumori 2010, 96:103-110.
5. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
6. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 10.1038/415530a, 11823860.
7. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10:529-541. 10.1016/j.ccr.2006.10.009, 17157792.
8. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobagyi GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008, 13:477-493. 10.1634/theoncologist.2007-0248, 18515733.
9. Pusztai L. Gene expression profiling of breast cancer. Breast Cancer Res 2009, 11:S11. 10.1186/bcr2430, 2797691, 20030862.
10. Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010, 28:1684-1691. 10.1200/JCO.2009.24.9284, 20194857.
11. Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, Fralick M, Kumar R, Clemons M. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 2009, 9:29-33. 10.3816/CBC.2009.n.005, 19299237.
12. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434. 10.1158/1078-0432.CCR-06-3045, 17671126.
13. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006, 24:5652-5657. 10.1200/JCO.2006.06.5664, 17116942.
14. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
15. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101:736-750. 10.1093/jnci/djp082, 2684553, 19436038.
16. Tutt A, Wang A, Rowland C, Gillett C, Lau K, Chew K, Dai H, Kwok S, Ryder K, Shu H, Springall R, Cane P, McCallie B, Kam-Morgan L, Anderson S, Buerger H, Gray J, Bennington J, Esserman L, Hastie T, Broder S, Sninsky J, Brandt B, Waldman F. Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. BMC Cancer 2008, 8:339. 10.1186/1471-2407-8-339, 2631011, 19025599.
17. Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EMJJ, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
18. Chang HY, Nuyten DSA, Sneddon JB, Hastie T, Tibshirani R, Sørlie T, Dai H, He YD, van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, van de Vijver MJ. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005, 102:3738-3743. 10.1073/pnas.0409462102, 548329, 15701700.
19. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826. 10.1056/NEJMoa041588, 15591335.
20. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005, 102:13550-13555. 10.1073/pnas.0506230102, 1197273, 16141321.
21. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98:262-272. 10.1093/jnci/djj052, 16478745.
22. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, Goldstein D, Piccart M, Delorenzi M. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008, 10:R65. 10.1186/bcr2124, 2575538, 18662380.
23. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008, 14:5158-5165. 10.1158/1078-0432.CCR-07-4756, 18698033.
24. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96. 10.1186/1471-2164-7-96, 1468408, 16643655.
25. Teschendorff A, Miremadi A, Pinder S, Ellis I, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007, 8:R157. 10.1186/gb-2007-8-8-r157, 2374988, 17683518.
26. Teschendorff A, Caldas C. A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer. Breast Cancer Res 2008, 10:R73. 10.1186/bcr2138, 2575547, 18755024.
27. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver M. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007, 9:R65. 10.1186/bcr1771, 2242660, 17910759.
28. Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D, Kreike B, Zhang Y, Wang Y, Ishwaran H, Foekens JA, van de Vijver M, Massagué J. Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci USA 2007, 104:6740-6745. 10.1073/pnas.0701138104, 1871856, 17420468.
29. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JGM, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007, 13:3207-3214. 10.1158/1078-0432.CCR-06-2765, 17545524.
30. Marron JS, Todd MJ, Ahn J. Distance-weighted discrimination. JASA 2007, 102:1267-1271.
31. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JGM, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007, 25:1239-1246. 10.1200/JCO.2006.07.1522, 17401012.
32. van de Vijver MJ, He YD, van 't Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009. 10.1056/NEJMoa021967, 12490681.
33. Broad Institute homepage. , http://www.broadinstitute.org/
34. Palmer C, Diehn M, Alizadeh A, Brown P. Cell-type specific gene expression profiles of leukocytes in human peripheral blood. BMC Genomics 2006, 7:115. 10.1186/1471-2164-7-115, 1479811, 16704732.
35. Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Bartels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, Niendorf A, Kroger N, Wenzel S, Leuwer R, Bokemeyer C, Hegewisch-Becker S, Atanackovic D. Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br J Cancer 2008, 99:930-938. 10.1038/sj.bjc.6604621, 2538749, 18781150.
36. Korkmaz B, Moreau T, Gauthier F. Neutrophil elastase, proteinase 3 and cathepsin G: Physicochemical properties, activity and physiopathological functions. Biochimie 2008, 90:227-242. 10.1016/j.biochi.2007.10.009, 18021746.
37. Uehara A, Sugawara Y, Sasano T, Takada H, Sugawara S. Proinflammatory cytokines induce proteinase 3 as membrane-bound and secretory forms in human oral epithelial cells and antibodies to proteinase 3 activate the cells through protease-activated receptor-2. J Immunol 2004, 173:4179-4189.
38. Liu J, Yue P, Artym VV, Mueller SC, Guo W. The role of the exocyst in matrix metalloproteinase secretion and actin dynamics during tumor cell invadopodia formation. Mol Biol Cell 2009, 20:3763-3771. 10.1091/mbc.E08-09-0967, 2777935, 19535457.
39. Nakagoe Nakagoe T, Fukushima Fukushima K, Itoyanagi Itoyanagi N, Ikuta Ikuta Y, Oka Oka T, Nagayasu Nagayasu T, Ayabe Ayabe H, Hara Hara S, Ishikawa Ishikawa H, Minami Minami H. Expression of ABH/Lewis-related antigens as prognostic factors in patients with breast cancer. J Cancer Res Clin Oncol 2002, 128:257-264. 10.1007/s00432-002-0334-5, 12029441.
40. Furuta J, Nobeyama Y, Umebayashi Y, Otsuka F, Kikuchi K, Ushijima T. Silencing of peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res 2006, 66:6080-6086. 10.1158/0008-5472.CAN-06-0157, 16778180.
41. Otsuka M, Kato M, Yoshikawa T, Chen H, Brown EJ, Masuho Y, Omata M, Seki N. Differential expression of the L-plastin gene in human colorectal cancer progression and metastasis. Biochem Biophys Res Commun 2001, 289:876-881. 10.1006/bbrc.2001.6047, 11735128.
42. Ivanova AV, Goparaju CMV, Ivanov SV, Nonaka D, Cruz C, Beck A, Lonardo F, Wali A, Pass HI. Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma. Clin Cancer Res 2009, 15:2602-2611. 10.1158/1078-0432.CCR-08-2755, 19351750.
43. Tatenhorst L, Senner V, Püttmann S, Paulus W. Regulators of G-protein signaling 3 and 4 (RGS3, RGS4) are associated with glioma cell motility. J Neuropathol Exp Neurol 2004, 63:210-222.
44. Puiffe ML, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, Tonin PN, Chevrette M, Provencher DM, Mes-Masson AM. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 2007, 9:820-829. 10.1593/neo.07472, 2040209, 17971902.
45. Nikolova D, Zembutsu H, Sechanov T, Vidinov K, Kee L, Ivanova R, Becheva E, Kocova M, Toncheva D, Nakamura Y. Genome-wide gene expression profiles of thyroid carcinoma: identification of molecular targets for treatment of thyroid carcinoma. Oncol Rep 2008, 20:105-121.
46. Xie Y, Wolff DW, Wei T, Wang B, Deng C, Kirui JK, Jiang H, Qin J, Abel PW, Tu Y. Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4. Cancer Res 2009, 69:5743-5751. 10.1158/0008-5472.CAN-08-3564, 2741027, 19549919.